IR@PKUHSC  > 北京大学第一临床医学院
学科主题临床医学
Kidney Cancer Working Group Report
Naito, Seiji1; Tomita, Yoshihiko2; Rha, Sun Young3; Uemura, Hirotsugu4; Oya, Mototsugu5; Song, He Zhi6; Zhong, Li Han7; Wahid, Mohamed Ibrahim Bin A.8
关键词Renal cell carcinoma Asia Guidelines Racial differences
刊名JAPANESE JOURNAL OF CLINICAL ONCOLOGY
2010-09-01
DOI10.1093/jjco/hyq127
suppl.1页:i51-i56
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]RENAL-CELL CARCINOMA ; JAPANESE PATIENTS ; INTERFERON-ALPHA ; PHASE-II ; SUNITINIB ; EFFICACY ; SAFETY ; SORAFENIB
英文摘要

Kidney cancer accounts for approximately 2% of all cancers worldwide, with renal cell carcinoma being the most common form and this report is focused on renal cell carcinoma. Globally, the incidence and mortality rates are increasing by 2-3% per decade. Kidney cancer is less common in Asia compared with the West. Cigarette smoking, obesity, acquired cystic kidney disease and inherited susceptibility are known risk factors for kidney cancer. The National Comprehensive Cancer Network Guidelines recommend surgical excision as first line of treatment for Stage I, II or III kidney cancer patients and Stage IV patients with resectable tumours. Immunotherapy has a 20-year history in treatment of metastatic kidney cancer. High-dose interleukin-2 (IL-2) is administered in some countries, whereas low-dose IL-2 and interferon-alpha (IFN-alpha) are popular in Japan. Molecular-targeted drugs, including sunitinib, bevacizumab and sorafenib, are being used for previously untreated and refractory patients. Asian and non-Asian populations have shown large differences in the incidences of adverse events with sorafenib and sunitinib. Consensus Statement: Kidney cancer is relatively uncommon in Asia compared with the West, but its incidence is increasing in more developed Asian nations. Guidelines from the National Comprehensive Cancer Network , etc., for treating metastatic renal cell carcinoma are based on Phase III clinical trials conducted primarily in Western patients. Targeted therapies are now becoming primary recommendations, but efficacy/toxicity data from Asian patients are lacking. Some drugs cause adverse effects in Asians because their recommended dosages are optimal for Caucasians but may be too high for Asians. Further research is necessary to develop optimal treatment strategies for Asians.

语种英语
WOS记录号WOS:000282175200008
引用统计
被引频次:25[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/66674
专题北京大学第一临床医学院
作者单位1.Yamagata Univ, Fac Med, Dept Urol, Yonezawa, Yamagata, Japan
2.Kyushu Univ, Grad Sch Med Sci, Dept Urol, Higashi Ku, Fukuoka 8128582, Japan
3.Yonsei Univ, Coll Med, Yonsei Canc Ctr, Canc Metastasis Res Ctr,Div Med Oncol, Seoul, South Korea
4.Peking Univ, Hosp 1, Chinese RCC Workgrp RCC Treatment Guideline, Dongcheng, Peking, Peoples R China
5.Peking Union Hosp, Dongcheng, Peking, Peoples R China
6.Kinki Univ, Sch Med, Dept Urol, Osaka 589, Japan
7.Keio Univ, Fac Med, Dept Urol, Shinjuku Ku, Tokyo, Japan
8.Malaysian Oncol Soc, Petaling Jaya, Malaysia
推荐引用方式
GB/T 7714
Naito, Seiji,Tomita, Yoshihiko,Rha, Sun Young,et al. Kidney Cancer Working Group Report[J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY,2010,suppl.1:i51-i56.
APA Naito, Seiji.,Tomita, Yoshihiko.,Rha, Sun Young.,Uemura, Hirotsugu.,Oya, Mototsugu.,...&Wahid, Mohamed Ibrahim Bin A..(2010).Kidney Cancer Working Group Report.JAPANESE JOURNAL OF CLINICAL ONCOLOGY,suppl.1,i51-i56.
MLA Naito, Seiji,et al."Kidney Cancer Working Group Report".JAPANESE JOURNAL OF CLINICAL ONCOLOGY suppl.1(2010):i51-i56.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Naito, Seiji]的文章
[Tomita, Yoshihiko]的文章
[Rha, Sun Young]的文章
百度学术
百度学术中相似的文章
[Naito, Seiji]的文章
[Tomita, Yoshihiko]的文章
[Rha, Sun Young]的文章
必应学术
必应学术中相似的文章
[Naito, Seiji]的文章
[Tomita, Yoshihiko]的文章
[Rha, Sun Young]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。